The emerging class of agents targeting factor XI/XIa offers the paradigm-shifting possibility of ‘haemostasis-sparing anticoagulation’: protection from stroke and other thromboembolic events with a benign bleeding profile. With three investigational agents now into late-phase development, two presentations delivered at the European Society of Cardiology (ESC) Congress 2024, one focusing on efficacy of the small molecule factor XIa inhibitor asundexian and one on safety of the monoclonal antibody factor XI inhibitor abelacimab, have added to our knowledge of this innovative and diverse class.
In this issue
Rate this content's potential impact on patient outcomes
Average rating / 5. Vote count:
No votes so far! Be the first to rate this content.